<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892017000200009</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Clinical characterization and survival of patients with multiple myeloma in a state of northeast brazilian]]></article-title>
<article-title xml:lang="es"><![CDATA[Caracterización clínica y supervivencia de pacientes con múltiple mieloma en un estado del noreste Brasil]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[da Silva Ferreira]]></surname>
<given-names><![CDATA[Kalyane]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rafael Maciel]]></surname>
<given-names><![CDATA[James Farley]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[de Souza Rego Pinto Carvalho]]></surname>
<given-names><![CDATA[Diana Paula]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Campos de Azevedo]]></surname>
<given-names><![CDATA[Isabelle]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fortes Vitor]]></surname>
<given-names><![CDATA[Allyne]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferreira Júnior]]></surname>
<given-names><![CDATA[Marcos Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Federal University or Fio Grande Health Science center department of Nursing]]></institution>
<addr-line><![CDATA[Natal RN]]></addr-line>
<country>Brazil</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Norte-Riograndense League Against Center  ]]></institution>
<addr-line><![CDATA[Natal RN]]></addr-line>
<country>Brazil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>33</volume>
<numero>2</numero>
<fpage>1</fpage>
<lpage>9</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892017000200009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892017000200009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892017000200009&amp;lng=en&amp;nrm=iso"></self-uri><kwd-group>
<kwd lng="en"><![CDATA[multiple myeloma]]></kwd>
<kwd lng="en"><![CDATA[plasmacytoma]]></kwd>
<kwd lng="en"><![CDATA[bone marrow]]></kwd>
<kwd lng="en"><![CDATA[epidemiology]]></kwd>
<kwd lng="es"><![CDATA[mieloma múltiple]]></kwd>
<kwd lng="es"><![CDATA[plasmocitoma]]></kwd>
<kwd lng="es"><![CDATA[médula ósea]]></kwd>
<kwd lng="es"><![CDATA[epidemiología]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ART&#205;CULO    ORIGINAL</b> </font></p>     <p>&nbsp; </p>     <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b> <font size="4">Clinical    characterization and survival of patients with multiple myeloma in a state of    northeast brazilian </font></b></font></p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> <font size="3"><b>Caracterizaci&#243;n    cl&#237;nica y supervivencia de pacientes con m&#250;ltiple mieloma en un estado    del noreste Brasil </b></font></font></p>     <p>&nbsp;</p>     <p align="center">&nbsp;</p>     <p align="left"><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Kalyane    da Silva Ferreira<sup>I</sup>, James Farley Rafael Maciel</b> <b><sup>II</sup></b>    <b>, Diana Paula de Souza Rego Pinto Carvalho</b> <b><sup>I</sup></b> <b> ,    Isabelle Campos de Azevedo<sup>I</sup>,<sup> </sup>Allyne Fortes Vitor<sup>I</sup>,    Marcos Antonio Ferreira J&#250;nior<sup>I</sup> </b> </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>I </sup> Department    of Nursing, Health Science Center, Federal University of Rio Grande do Norte,    Natal/RN, Brazil.     <br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><sup>II </sup>    Norte-Riograndense League Against Cancer, Natal/RN, Brazil. </font></p>     ]]></body>
<body><![CDATA[<p>&nbsp; </p>     <p>&nbsp;</p> <hr>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b>    </font></p>     <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Introduction:    </b> The annual prevalence of Multiple Myeloma in patients aged between 65 and    74 years old is 31 cases for every 100 000 people and increases to 46 cases    per 100 000 people in patients older than 75 years old. <br/>   <b>Objectives</b> : To clinically characterize patients with multiple myeloma    treated at a referral center in the state of Rio Grande do Norte, Brazil, and    to estimate their survival. <br/>   <b>Methods</b> : Retrospective cohort study. For data collection, secondary    sources listed in the cadastral database and complementation with data records    was used. The descriptive analysis was performed by using the Epi Info program,    version 3.5.2 and the survival analysis used Statistic Package for Social Sciences    (SPSS) software version 22. <br/>   <b>Results</b> : Out of the 39 patients studied, 17 (43.6%) were male, and 22    (56.4%) were female, with an average age of 66.3 years old. The main medication    therapeutic regimen was the combination of Cyclophosphamide, Thalidomide, and    Dexamethasone (CTD), as the most medical prescription used in 63.6% of cases.    Only 38.5% had other comorbidities and 46.2% of patients developed plasmacytoma.    In the International Staging System (ISS), stage III prevailed with 30.8% among    the evaluated patients. The cumulative probability of global survival rate showed    a disease with a survival rate of 50% of the sample in about 36 months (three    years) after diagnosis is confirmed. </font></p>     <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Keywords</b>    : multiple myeloma; plasmacytoma; bone marrow; epidemiology.</font></p> <hr>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>RESUMEN</b>    </font></p>     <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b>Introducci&#243;n:    </b> la prevalencia anual de mieloma m&#250;ltiple en pacientes entre 65 y 74    a&#241;os de edad es de 31 casos por cada 100 000 personas y aumenta a 46 casos    por 100 000 personas en pacientes mayores de 75 a&#241;os. <b> <br/>   Objetivos: </b> caracterizar cl&#237;nicamente a los pacientes con mieloma m&#250;ltiple    tratados en un centro de referencia en el estado de Rio Grande do Norte, Brasil,    y estimar su supervivencia. <b> <br/>   M&#233;todos: </b> estudio de cohorte, retrospectivo. Para la recopilaci&#243;n    de datos, se utilizaron fuentes secundarias de la base de datos catastral y    complementaci&#243;n con registros de datos. El an&#225;lisis descriptivo se    realiz&#243; mediante el programa Epi Info, versi&#243;n 3.5.2 y el an&#225;lisis    de supervivencia del software estad&#237;stico SPSS 22. <br/>   <b>Resultados: </b> de los 39 pacientes estudiados, 17 (43,6 %) eran varones    y 22 (56,4 %), mujeres; con una edad promedio de 66,3 a&#241;os. El principal    r&#233;gimen terap&#233;utico de medicaci&#243;n fue la combinaci&#243;n de    ciclofosfamida, talidomida y dexametasona (CTD), como la prescripci&#243;n m&#233;dica    m&#225;s utilizada en el 63,6 % de los casos. Solo el 38,5 % ten&#237;a otras    comorbilidades y el 46,2 % de los pacientes desarroll&#243; plasmocitoma. En    el <i>International Staging System</i> (ISS), prevaleci&#243; la etapa III (30,8    % de los pacientes evaluados). La probabilidad acumulada de supervivencia global    mostr&#243; una enfermedad con una tasa de supervivencia del 50 % de la muestra    en aproximadamente 36 meses (tres a&#241;os) despu&#233;s de que se confirm&#243;    el diagn&#243;stico. </font></p>     <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b> Palabras clave:    </b> mieloma m&#250;ltiple; plasmocitoma; m&#233;dula &#243;sea; epidemiolog&#237;a.</font></p> <hr>     <p>&nbsp;</p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b> <br clear="all"/> </b> </font>      <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b><font size="3">INTRODUCTION</font></b>    </font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Multiple Myeloma    (MM) is a monoclonal differentiated B cells tumor that synthesizes a monoclonal    protein, and it is reproduced predominantly in the bone marrow. With a consequent    production of defective monoclonal immunoglobulins associated with multiple    organ dysfunctions, it is 1% of all malignancies in general and 10% of hematological    cancer <sup>1-3</sup>. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> The annual prevalence    of MM in patients aged between 65 and 74 years old is 31 cases for every 100,000    people and increases to 46 cases per 100,000 people in patients older than 75    years old<sup>4</sup>. As to gender, this type of cancer is more common in the    male population and despite being present in all ethnic groups, it is higher    in black population<sup>5</sup>. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> The MM is difficult    to diagnose, and it can present non-specific or vague symptoms. Therefore, when    there is suspicion of myeloma, many investigations must be conducted, including    the anamnesis with an approach to family history and physical examination aided    by the general laboratory tests of hematological order, radiological evaluation    of the skeleton, among others. Immunofixation is the "gold standard" method    considered for confirmation of MM diagnosis, which allows identification of    monoclonal protein and the heavy and light chains involved, with a sensitivity    of 41% when used as an isolation testing and a specificity of 100%<sup>6,7</sup>.    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> In the United    States, about 22,000 Americans are diagnosed each year with MM, and approximately    11,000 die from this disease. Brazil does not have exact statistics, only an    estimate that there are about 30,000 patients with MM under treatment<sup>8</sup>.    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Concerning the    therapeutic field of MM, it has undergone significant changes over the last    ten years, directly influencing the increased survival and improving the quality    of life for patients. Life expectancy increased from less than three years for    up to seven years on average. This fact was possible after the introduction    of new medication such as thalidomide, lenalidomide, bortezomib and autologous    bone marrow transplantation as a therapeutic option<sup>8</sup>. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> The MM is a heterogeneous    disease, and patients are not treated in the same way<sup>9</sup>. Therefore,    the International Myeloma Working Group (IMWG) prepared the International Staging    System (ISS), which is a more objective classification of patients based on    &#223;2-microglobulin and albumin levels, classifying patients with MM in three    groups with different overall survival: 62 months, 44 months and 29 months for    the stages 1, 2 and 3, respectively. Currently, it is the staging system most    used for patients with MM<sup>10</sup>. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> The MM has no    cure. Thus, the main challenge for the health team is to keep patients in treatment    and provide them a survival with quality. For this, it is necessary to know    and characterize the population affected by this condition. Thus, this study    aimed to characterize patients clinically with Multiple Myeloma treated at a    referral center in the state of Rio Grande do Norte, and to estimate their survival.    </font></p>     <p>&nbsp;</p>     <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b><font size="3">METHODS</font></b>    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> It is a retrospective    cohort study of the evidence base that included patients with a diagnosis of    Multiple Myeloma (MM), assisted by the hematology department of a referral service    in the state of Rio Grande do Norte, Brazil, from January 2001 to December 2014.    </font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> To collect data    from the participants in the study, secondary sources of the registration database    in specialized medical service to care for patients with MM were used and complementation    with data records. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Patients from    both genders and all ages accompanied or followed up within the period studied,    with a confirmed medical diagnosis of the disease in question, and available    in full were included in the sample. Those who did not have a confirmed diagnosis,    as well as a suggestive or diagnostic elucidation and those who did not have    all the information needed to reach the proposed goals were excluded. The final    sample consisted of 39 patients. The data collection period occurred between    January and March 2015. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> The diagnostic    confirmation dates, the follow-up time in service and time of closure for the    cases of death and abandonment were analyzed. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Data was organized    through Microsoft Excel<sup>&#174; </sup>for descriptive analysis using Epi    Info 2002 program, version 3.5.2. For survival analysis, the Statistic Package    for Social Sciences software (SPSS), version 22 was used. The survival calculations    were determined by Kaplan-Meier method when the starting point was the date    of the medical diagnosis confirmation and the final date of death or abandonment.    The comparison of survival was performed using the statistical method for the    Log Rank<sup>11,12</sup>. The significance level 0.05 was considered for this    study. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> The research protocol    of this study was approved by the Research Ethics Committee of the North Riograndense    League Against Cancer in its ethical and methodological aspects, according to    the resolution in CNS 466/2012, under n&#176; 827,933 and CAAE 36181314.6.0000.5293.    </font></p>     <p>&nbsp;</p>     <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b><font size="3">RESULTS</font></b>    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Out of 39 patients    studied, 17 (43.6%) were male and 22 (56.4%) female. The age ranged between    37 and 82 years old, with an average of 66.3 and a higher frequency (76.6%)    aged over 60 years old. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> <a href="/img/revistas/hih/v33n2/t01_509.gif">Table    1</a> describes the sample, describing the frequency of age groups, gender,    hematopoietic stem cell transplantation, post-transplant response and drug treatment.    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> <a href="/img/revistas/hih/v33n2/t02_509.gif">Table    2</a> addresses the cumulative probability of overall survival of the patients    and gender. Significant value for the association of the gender variable in    the outcome of survival was not found, as shown in <a href="#f1">Figures 1</a>    and <a href="#f2">2</a>. </font></p>     ]]></body>
<body><![CDATA[<p align="center"><a name="f1"></a><img src="/img/revistas/hih/v33n2/f01_509.gif" width="509" height="416"></p>     <p align="center"><a name="f2"></a><img src="/img/revistas/hih/v33n2/f02_509.gif" width="470" height="409"></p>     <p>&nbsp; </p>     <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b><font size="3">DISCUSSION</font></b>    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> The data presented    in the study indicated that the MM often affects elderly patients when the average    age of the sample was 66.3 years old, and only 2.6% were younger than 40 years    old. A study in Cuba found that the mean age of patients was 60.7 years old,    and only 6.8% of cases were under 40 years old (13). A study in southern Brazil    showed a mean age of the study sample of 68.3 years old, emphasizing the frequency    of MM in the elderly population<sup>14</sup>. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> However, a study    conducted in China found an average age of 59 years old and brings as a possible    explanation for this result, unlike Western countries, ethnic diversity, but    more in-depth investigations are needed for the explanation of this difference<sup>15</sup>.    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Regarding gender,    there was a slight predominance of females (56.4%), which diverges from the    literature and may have its occurrence justified by the size of the sample.    In the study conducted in China, there was a predominance of males (53.5%),    while in Cuba, the ratio found was 1.7:1 for males<sup>13,15</sup>. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> On the therapeutic    drug regimen, the combination of cyclophosphamide, thalidomide, and dexamethasone    (CTD) was the most therapeutic indication used by patients with a percentage    of 63.6% of cases, while 20.4% were submitted to Hematopoietic Stem Cells Transplantation    and 50% had a complete response after transplantation. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Similar to this    result, a survey conducted in Japan evaluated the effects of prognostic factors    on the outcome of patients with MM after Autologous Hematopoietic Stem Cell    Transplantation (HSCT), and 44.7% of patients achieved a complete response,    24.7% had very good partial response and 21.2% had partial response and concluded    that high-dose chemotherapy supported by autologous stem cells in patients with    advanced MM are safe, effective and are associated with a high rate of complete    response <sup>16</sup>. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Within the sample    assessed, only 38.5% of patients had other comorbidities related to the MM prognosis.    However, a study carried out in Italy showed vulnerability characteristics such    as the number of co-morbidities, increases with age, but 30% of patients younger    than 65 years old may have the same characteristics, suggesting that chronological    age does not fully explain the vulnerability of the patient, but these characteristics    significantly affect the survival of the patient, regardless of age <sup>17</sup>.    </font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> It was found a    frequency of 46.2% of patients who developed plasmacytoma as opposed to 53.8%    who did not in this study. This finding converges with that found in another    study, in which in a sample of 88 patients, only 13 cases were diagnosed with    plasmacytoma, located mainly in the ribs (25%) followed by the vertebrae (18.8%),    skull (12.5 %) and the same percentage (6.3%) in the sphenoid, the humerus,    the clavicle, lung, central nervous system (meninges), skin and testicles<sup>13</sup>.    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> The cumulative    probability of overall survival found in this study showed a disease with a    survival rate of 50% around 36 months (three years) after the diagnosis confirmed,    no major differences compared between the genders, despite a slightly increased    survival of male patients, with no statistical significance for this value (p=0.747).    In general, the cumulative probability of overall survival was 97%, 72%, 34%,    19% and 9% for intervals of 12, 24, 48, 72 and 120 months, respectively. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> A study conducted    in southern Brazil on the survival of MM patients showed a median survival of    37.53 &#177; 29.41 months with a range from one to 122 months from diagnosis.    The main study variable that showed statistical significance for survival was    the presence of renal failure as a comorbidity (p=0.026), in which the average    survival of patients who developed it was 39.26 months<sup>14</sup>, approximate    results found in this study. </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Against these    results, another study with a larger sample (88 patients) showed that patients    younger than 70 years old had a higher survival rate (6.5 years) compared to    the cases that were younger, with a survival of 3.8 years, although they were    not as significant from a statistical point of view (p=0.188)<sup>13</sup>.    </font></p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> The main limitations    of this study are linked to the number of subjects in the final sample (n=39)    analyzed, which in the case of a low value compromises the interpretation of    data so that they can be generalized inferences and generate more property.    The main biases are also associated with the fact that this is a retrospective    study with secondary data collection, despite the care for the insertion of    the subjects analyzed are only those provided complete, clear and explanatory    data to reach the proposed goals. </font></p>     <p>&nbsp;</p>     <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><b><font size="3">REFERENCES</font></b>    </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 1. Donk van NWCJ,    Sonneveld P. Diagnosis and Risk Stratification in Multiple Myeloma. Hematol    Oncol Clin. 2014 Oct; 28(5):791-813.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 2. Palumbo A,    Anderson K. Multiple myeloma. New Engl J Med. 2011;364(24):1046-60.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 3. Bohsain OJ.    Quality of life in patients with multiple myeloma treated with percutaneous    Vertebroplasty. Coluna/Columna. 2014 Jan/Mar;13(1):53-6.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 4. Palumbo A,    Bringhen S, Ludwig H, Dimopoulos MA, Blad&#233; J, Mateos MV, et al. Personalized    therapy in multiple myeloma according to patient age and vulnerability: a report    of the European Myeloma Network (EMN). Blood. 2011 Oct;118(27):4519-29.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 5. Ferreira K.    Plasma Cell Myeloma: Literature Review and Case Study. Clin Lab Sci. 2013; 26(4):187-95.        </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 6. Dowling M,    Kelly M, Meenaghan T. Promoting quality of life for patients with myeloma. Cancer    Nursing Practice. 2013 Oct;12(8):30-7.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 7. Fr&#233;bet    E, Abraham J, Genevi&#232;ve F, Lepelley P, Daliphard S, Bardet V. Immunologique    des Leuc&#233;mies Study Group. A GEIL flow cytometry consensus proposal for    quantification of plasma cells: application to differential diagnosis between    MGUS and myeloma. Cytometry B Clin Cytom. 2011 May;80(3):176-85.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 8. Maiolino A.    Panorama do mieloma m&#250;ltiplo. Onco&amp;. 2013 May/June;20-22.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 9. Mikrael JR,    Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of Newly    Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma    and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc.    2013 Apr;88(4):360-76.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 10. Paszekova    H, Kryukov F, Kubiczkova L, Hajek R, Sevcikova S. High-Risk Multiple Myeloma:    Different Definitions, Different Outcomes? Clin Lymphoma, Myeloma Leuk. 2014    Feb;12(1):423-32.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 11. Callegari-Jacques    SM. Bioestat&#237;stica: princ&#237;pios e aplica&#231;&#245;es. Porto Alegre:Artmed;    2003.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 12. Dawson B,    Trapp RG. An&#225;lise dos temas de pesquisa sobre sobreviv&#234;ncia. In: Dawson    B, Trapp RG. Bioestat&#237;stica b&#225;sica e cl&#237;nica. Rio de Janeiro:    McGrawHill; 2003. p. 187-205.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 13. Ram&#243;n    Rodr&#237;guez LG, Rivera Keeling C, Arencibia N&#250;&#241;ez A, Avila Cabrera    OM, Izquierdo Cano L, Espinosa Estrada EE, et al. Caracterizaci&#243;n cl&#237;nica    y de laboratorio del mieloma m&#250;ltiple en el Instituto de Hematolog&#237;a    e Inmunolog&#237;a. Rev Cubana Hematol Inmunol Hemoter. 2013 Oct/Dec;29(4):382-97.        </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 14. Sakae TM,    Santos FAN, Baldessar MZ. Sobrevida de pacientes portadores de mieloma m&#250;ltiplo    atendidos em hospital de refer&#234;ncia no Sul de Santa Catarina. Rev Bras    Clinic Med. 2010;8(3):216-21.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 15. Geng C, Liu    N, Yang G, Liu A, Leng Y, Wang H, et al. Retrospective analysis of 264 multiple    myeloma patients. Oncol Lett. 2013 Feb;5(2):707-13.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 16. Kumar L, Cyriac    SL, Tejumurtula T, Bahl A, Biswas B, Ranjit K, et al. Autologous Stem Cell Transplantation    for Multiple Myeloma: Identification of Prognostic Factors. Clin Lymphoma Myeloma    Leuk. 2013 Feb;13(1):32-41.     </font></p>     <!-- ref --><p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> 17. Offidani M,    Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M, et al. Assessment    of Vulnerability Measures and Their Effect on Survival in a Real-Life Population    of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry.    Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):423-32.     </font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana, Arial, Helvetica, sans-serif" size="2"> Recibido: julio    19, 2016.     <br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">Aceptado:    diciembre 12, 2016. </font></p>     <p>&nbsp;</p>     <p>&nbsp; </p>     <p> <font face="Verdana, Arial, Helvetica, sans-serif" size="2"><i>Isabelle Campos    de Azevedo</i> . Universidade Federal do Rio Grande do Norte, Centro de Ci&#234;ncias    da Sa&#250;de, Departamento de Enfermagem. Avenida Salgado Filho, S/N, Lagoa    Nova, Natal/RN, Brasil. CEP: 59078970. Fax: 55-084-32153615.    <br>   </font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">E-mail: <a href="mailto:marcos_nurse@hotmail.com">isabellebr2511@gmail.com</a>    </font></p>      ]]></body>
<back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Donk van]]></surname>
<given-names><![CDATA[NWCJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sonneveld]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diagnosis and Risk Stratification in Multiple Myeloma]]></article-title>
<source><![CDATA[Hematol Oncol Clin]]></source>
<year>2014</year>
<month>10</month>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>791-813</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palumbo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Multiple myeloma]]></article-title>
<source><![CDATA[New Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>1046-60</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bohsain]]></surname>
<given-names><![CDATA[OJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Quality of life in patients with multiple myeloma treated with percutaneous Vertebroplasty]]></article-title>
<source><![CDATA[Coluna/Columna]]></source>
<year>2014</year>
<month> J</month>
<day>an</day>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palumbo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bringhen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ludwig]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dimopoulos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Bladé]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mateos]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2011</year>
<month>10</month>
<volume>118</volume>
<numero>27</numero>
<issue>27</issue>
<page-range>4519-29</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Plasma Cell Myeloma: Literature Review and Case Study]]></article-title>
<source><![CDATA[Clin Lab Sci]]></source>
<year>2013</year>
<volume>26</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>187-95</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dowling]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Meenaghan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Promoting quality of life for patients with myeloma]]></article-title>
<source><![CDATA[Cancer Nursing Practice]]></source>
<year>2013</year>
<month>10</month>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>30-7</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frébet]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Geneviève]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lepelley]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Daliphard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bardet]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<collab>Immunologique des Leucémies Study Group</collab>
<article-title xml:lang="en"><![CDATA[A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma]]></article-title>
<source><![CDATA[Cytometry B Clin Cytom]]></source>
<year>2011</year>
<month> M</month>
<day>ay</day>
<volume>80</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>176-85</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maiolino]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Panorama do mieloma múltiplo]]></article-title>
<source><![CDATA[Onco &]]></source>
<year>2013</year>
<month> M</month>
<day>ay</day>
<page-range>20-22</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mikrael]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Dingli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Reeder]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Buadi]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
<name>
<surname><![CDATA[Hayman]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013]]></article-title>
<source><![CDATA[Mayo Clin Proc]]></source>
<year>2013</year>
<month>04</month>
<volume>88</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>360-76</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paszekova]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kryukov]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Kubiczkova]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hajek]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sevcikova]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?]]></article-title>
<source><![CDATA[Clin Lymphoma, Myeloma Leuk]]></source>
<year>2014</year>
<month>02</month>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>423-32</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Callegari-Jacques]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<source><![CDATA[Bioestatística: princípios e aplicações]]></source>
<year>2003</year>
<publisher-loc><![CDATA[Porto Alegre ]]></publisher-loc>
<publisher-name><![CDATA[Artmed]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dawson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Trapp]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Análise dos temas de pesquisa sobre sobrevivência]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Dawson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Trapp]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<source><![CDATA[Bioestatística básica e clínica]]></source>
<year>2003</year>
<page-range>187-205</page-range><publisher-loc><![CDATA[Rio de Janeiro ]]></publisher-loc>
<publisher-name><![CDATA[McGrawHill]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramón Rodríguez]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera Keeling]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Arencibia Núñez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Avila Cabrera]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
<name>
<surname><![CDATA[Izquierdo Cano]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa Estrada]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
</person-group>
<article-title xml:lang="es"><![CDATA[Caracterización clínica y de laboratorio del mieloma múltiple en el Instituto de Hematología e Inmunología]]></article-title>
<source><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></source>
<year>2013</year>
<month> O</month>
<day>ct</day>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>382-97</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakae]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[FAN]]></given-names>
</name>
<name>
<surname><![CDATA[Baldessar]]></surname>
<given-names><![CDATA[MZ]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Sobrevida de pacientes portadores de mieloma múltiplo atendidos em hospital de referência no Sul de Santa Catarina]]></article-title>
<source><![CDATA[Rev Bras Clinic Med]]></source>
<year>2010</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>216-21</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Leng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Retrospective analysis of 264 multiple myeloma patients]]></article-title>
<source><![CDATA[Oncol Lett]]></source>
<year>2013</year>
<month>02</month>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>707-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cyriac]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Tejumurtula]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Bahl]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Biswas]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ranjit]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autologous Stem Cell Transplantation for Multiple Myeloma: Identification of Prognostic Factors]]></article-title>
<source><![CDATA[Clin Lymphoma Myeloma Leuk]]></source>
<year>2013</year>
<month>02</month>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>32-41</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Offidani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Corvatta]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Polloni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Centurioni]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Visani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brunori]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Assessment of Vulnerability Measures and Their Effect on Survival in a Real-Life Population of Multiple Myeloma Patients Registered at Marche Region Multiple Myeloma Registry]]></article-title>
<source><![CDATA[Clin Lymphoma Myeloma Leuk]]></source>
<year>2012</year>
<month>12</month>
<volume>12</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>423-32</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
